For use in horses.

Incorporating PRASCEND tablets into a PPID management protocol has been shown to reduce clinical signs of the disease and enhance horses’ overall quality of life. Clinical research and real-world evidence show that horses treated with PRASCEND: • Are supported with the only therapy for PPID approved by the FDA. • Showed improved clinical signs within 3 months, with continued improvement at 6 months. • Experienced significant improvement in delayed shedding (89%), muscle wasting, abnormal fat distribution, and abnormal sweating within 6 months. • Achieved a 76.1% overall treatment success rate based on clinical signs and endocrine testing. • Sustained improvement and owner satisfaction in a long-term study, with 87% of owners reporting they would choose PRASCEND again for another PPID horse. • Benefit from consistent, reliable dosing and potency, unlike compounded pergolide products, which have been shown to lose effectiveness rapidly.

When a horse has PPID, the pituitary gland overproduces hormones, making it difficult to keep bodily functions in a healthy working state, resulting in a variety of clinical signs. Prascend tablets act to curb the overproduction and secretion of these hormones to better control clinical signs.

The most common adverse effect is decreased appetite, which is typically mild. If severe, your veterinarian may recommend a temporary dose adjustment.

Pergolide, as pergolide mesylate

Contact your closest emergency pet hospital.

Warnings: • Not for use in horses intended for human consumption. • PRASCEND® tablets should not be crushed due to the potential for increased human exposure. • Keep in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose. Dogs have eaten PRASCEND tablets dropped during administration. • Adverse reactions may occur if animals other than horses ingest PRASCEND tablets. • Contraindicated in horses with hypersensitivity to pergolide mesylate or other ergot derivatives. US-EQU-0392-2025 Caution/Precautions: Treatment with PRASCEND® (pergolide tablets) may cause inappetence. The use of PRASCEND in breeding, pregnant, or lactating horses has not been evaluated. The effects of pergolide mesylate on breeding, pregnant, or lactating horses are not known; however, the pharmacologic action of pergolide mesylate suggests that it may interfere with reproductive functions such as lactation. PRASCEND is approximately 90% associated with plasma proteins. Use caution if administering PRASCEND with other drugs that affect protein binding. Dopamine antagonists, such as neuroleptics (phenothiazines, domperidone) or metoclopramide, ordinarily should not be administered concurrently with PRASCEND (a dopamine agonist) since these agents may diminish the effectiveness of PRASCEND tablets. Keep PRASCEND in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose. Dogs have eaten PRASCEND tablets that were placed in food intended for horses or dropped during administration of the tablets to the horses. Adverse reactions may occur if animals other than horses ingest PRASCEND tablets. PRASCEND is contraindicated in horses with hypersensitivity to pergolide mesylate or other ergot derivatives.

Prascend (pergolide tablets) are available in 1 mg strength – packaged 10 tablets per blister and 60 or 160 tablets per carton.

Boehringer Ingelheim